Search

Tacrine

Tacrine has been discontinued for the United States market. … A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous

Flucytosine

A fluorinated cytosine analog that is used as an antifungal agent.

Avibactam

As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract

Carboplatin

[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]

Ethoxzolamide

Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

Strontium chloride

This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents instead [A33167, A33168].

Ixazomib

[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.

Chromic nitrate

Aluminum zirconium octachlorohydrex gly

Interestingly, this chemical has been studied in relation to its possible impact on the microbiome of the human underarms [A32967]. … The anhydrous form of the compound also has water-absorbing properties. Currently, the FDA allows the inclusion of this substance in concentrations of up to 20% in antiperspirants [L2012].

Almonertinib

[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.